No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 5.6x · 10Y median 0.8x · 99th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 25
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:02:08.107Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for iSpecimen Inc. (ISPC) stock was $1.05 as of Oct 6, 2026, 9:54 AM EDT, down 0.48% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -97.7% · 3-year avg -87.1%/yr · 5-year avg -81.1%/yr
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials.
Medical - Diagnostics & Research · Woburn, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-152.00
vs Estimate
$-224.00
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ISPC | $2.63M | $1.04 | -0.48% | -97.66% | -81.14% | N/A | N/A |
| 2BIAF | $2.62M | $6.25 | +0.97% | -84.05% | N/A | N/A | vs ISPC |
| 3JAGX | $2.67M | $6.15 | +30.02% | N/A | N/A | N/A | vs ISPC |
| 4MBRX | $2.51M | $0.47 | -1.38% | -95.81% | -78.48% | -64.00% | vs ISPC |
| 5FBLG | $2.50M | $1.20 | +1.27% | -89.14% | N/A | N/A | vs ISPC |
| 6ITOC | $2.38M | $0.25 | +1.85% | N/A | N/A | N/A | vs ISPC |
N/A
$151940.00
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.04
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $-184.00 | $-184.00 | $-184.00 | 1 |
| Quarter ending Mar 2027 | $-200.00 | $-200.00 | $-200.00 | 1 |
| Quarter ending Jun 2027 | $-220.00 | $-220.00 | $-220.00 | 1 |
| Quarter ending Sep 2027 | $-272.00 | $-272.00 | $-272.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $3.50M | $3.50M | $3.50M | 1 |
| Quarter ending Mar 2027 | $2.78M | $2.78M | $2.78M | 1 |
| Quarter ending Jun 2027 | $2.87M | $2.87M | $2.87M | 1 |
| Quarter ending Sep 2027 | $2.45M | $2.45M | $2.45M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $37.85M | $37.85M | $37.85M | 1 |
